USP5 inhibition enables potential therapy for t(8;21) AML through ubiquitin-mediated AML1-ETO degradation in patient-derived xenografts | Science Translational Medicine
A selective USP5 inhibitor suppresses t(8;21) AML progression by selectively degrading AML1-ETO in PDX models.
